Cargando…

Comments on Cui Q‐Q et al: “Hippocampal CD 39/ENTPD 1 promotes mouse depression‐like behavior …”

Comment on Hippocampal CD 39/ENTPD 1 promotes mouse depression‐like behavior through hydrolyzing extracellular ATP by Cui et al [Image: see text]

Detalles Bibliográficos
Autor principal:	Zimmermann, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507361/ https://www.ncbi.nlm.nih.gov/pubmed/32789954 http://dx.doi.org/10.15252/embr.202050737

Ejemplares similares

Reply to Q. Chu et al
por: Semprini, Jason T., et al.
Publicado: (2021)

Deletion of Cd39/Entpd1 Results in Hepatic Insulin Resistance
por: Enjyoji, Keiichi, et al.
Publicado: (2008)

The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis
por: Peng, Zhen‐Wei, et al.
Publicado: (2017)

Response to comment by Moxon et al.
por: Thompson, Dawn, et al.
Publicado: (2018)

Response to comment by Guerra et al.
por: Yang, Xinyue, et al.
Publicado: (2018)

Response to comment from Brasky et al.
por: Verdoodt, F., et al.
Publicado: (2016)

Authors’ reply to the comment from Uchida et al.
por: Osawa, Itsuki, et al.
Publicado: (2023)

Authors’ reply to the comment from Glass et al.
por: Kotani, Yuki, et al.
Publicado: (2023)

Comment on the exchange between Boddy et al. and Wagner et al.: malignancy, placentation and litter size
por: Haig, David
Publicado: (2020)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Authors’ reply to the comment from Benavides-Zora et al.
por: Kotani, Yuki, et al.
Publicado: (2023)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023)

Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.
por: Chen, Guang, et al.
Publicado: (2022)

Metformin and cancer: Quo vadis et cui bono?
por: Menendez, Javier A., et al.
Publicado: (2016)

Cui Bono?
Publicado: (1869)

On the History of dermatology: the study of skin diseases over the centuries - Response to the observations and comments by Mirzaei MR et al. and Rashmi TM et al()()
por: Ferreira, Iago Gonçalves, et al.
Publicado: (2021)

Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020
por: Oliver, Thomas Richard William, et al.
Publicado: (2020)

Corrosion under insulation (CUI) guidelines: technical guide for managing CUI
por: De Landtsheer, Gino
Publicado: (2020)

Cryobiopsy Compared with Surgical Lung Biopsy in ILD: Reply to Maldonado et al., Froidure et al., Bendstrup et al., Agarwal et al., Richeldi et al., Rajchgot et al., and Quadrelli et al.
por: Romagnoli, Micaela, et al.
Publicado: (2019)

Comment on: “Fibroblast growth factor 21 controls mitophagy and muscle mass” by Oost et al.
por: Wu, Yeshun, et al.
Publicado: (2019)

Comment on Parker et al. (Evolution, Medicine and Public Health 2021;9:120–30.)
por: Rook, Graham A.W.
Publicado: (2021)

Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
por: Chiu, David Kung-Chun, et al.
Publicado: (2017)

Reply by Gattinoni et al. to Hedenstierna et al., to Maley et al., to Fowler et al., to Bhatia and Mohammed, to Bos, to Koumbourlis and Motoyama, and to Haouzi et al.
por: Gattinoni, Luciano, et al.
Publicado: (2020)

Profile of Yi Cui
por: Ravindran, Sandeep
Publicado: (2023)

Comment on: “Pitfalls in the measurement of muscle mass: a need for a reference standard” by Buckinx et al.
por: Clark, Brian C., et al.
Publicado: (2019)

Comment on Tauriainen et al.: Serum, liver and bile sitosterol and sitostanol in obese patients with and without NAFLD
por: Plat, Jogchum, et al.
Publicado: (2018)

Reply to Cottin et al., to Johannson et al., to Scholand and Wells, and to Crowley et al.
por: Raghu, Ganesh, et al.
Publicado: (2022)

Reply to Lescoat et al. and to Khamis et al.
por: Adegunsoye, Ayodeji, et al.
Publicado: (2019)

Reply to Chase et al. and to Milner et al.
por: Mittel, Aaron M., et al.
Publicado: (2020)

Reply by Xu et al. to Haouzi et al.
por: Xu, Yonghao, et al.
Publicado: (2020)

Reply by Pan et al. to Haouzi et al.
por: Pan, Chun, et al.
Publicado: (2020)

Reply to Topeli et al. and to Akinosoglou et al.
por: Azevedo, Luciano C. P., et al.
Publicado: (2020)

Reply to Turnbull et al. and to Hulme et al.
por: Breuer, Oded, et al.
Publicado: (2020)

Reply to Shoemark et al. and to Shapiro et al.
por: Amirav, Israel, et al.
Publicado: (2020)

Reply to Gueret et al. and to Hammond et al.
por: Brown, Ryan M., et al.
Publicado: (2020)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

Reply to Sanfilippo et al. and to Caviedes et al.
por: Arachchillage, Deepa J., et al.
Publicado: (2021)

Reply to Jin et al. and to Sun et al.
por: Boucly, Athénaïs, et al.
Publicado: (2021)

Reply to Nie et al. and Bhammar et al.
por: Peters, Michael C., et al.
Publicado: (2022)

Reply to Fillatre et al. and Li et al.
por: Abdul-Aziz, Mohd H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l0npim98nq0233g069cccntgg9